CanSense-CRC: early detection of colorectal cancer

CanSense-CRC：结直肠癌的早期检测

• 批准号: 10068039
• 金额: $ 44.73万
• 依托单位: CANSENSE LTD
• 依托单位国家: 英国
• 项目类别: Collaborative R&D
• 财政年份: 2023
• 资助国家: 英国
• 起止时间: 2023 至 无数据
• 项目状态: 未结题
• 来源: https://gtr.ukri.org/projects?ref=10068039
• 关键词: CanSense; CRC; early; detection; colorectal

**Aim**The aim of our research project is to develop a blood test to detect the earliest stages of colorectal (bowel) cancer. Detecting cancer early allows it to be treated more simply and effectively, making it more likely to be curable.The blood test could help GPs refer patients with bowel symptoms to hospitals more effectively. The test would allow a faster diagnosis of cancer to allow treatment to start sooner. The test can also be used to help prioritise patients for check colonoscopies after treatment of bowel cancer and removal of bowel polyps.**Background**Bowel cancer is a leading cause of cancer related deaths worldwide. Early detection can cure the cancer but as symptoms of bowel cancer are vague it is difficult to diagnose early. Many symptomatic patients are referred for a costly and unpleasant colonoscopy. Most colonoscopies prove to be normal and could be avoided. The large number of referrals delays those who do in fact have underlying cancer being seen. There is a real need for faster and less invasive detection methods.Our test uses lasers to detect cancer activity in the blood. A computer program analyses the signal to say if cancer is likely or not. Early results indicate that the blood test is highly accurate at detecting bowel cancer and the polyps that can turn cancerous.**Methods**This project will develop the testing device and the software program to be ready for NHS use. We will study the staff who will be using the device (doctors, those who take the blood sample and laboratory staff) to improve its overall design. This will reduce any risks of its use to make it as safe as possible. We will also see if the test can save costs.The project has 2 workstreams:1\. To test and improve the safety of the device through working with those who will use it.2\. Conduct an economic cost/benefit analysis of the product compared to current tests**Patient/Public Involvement**We have involved patients from the start of our project - confirming that the need for an acceptable and accessible cancer blood test is at the heart of our development. We will work with patients and the public to design, deliver and disseminate our project.**Dissemination**We will share our results through government, academic, NHS and PPI partners, social media, publications and news releases to help achieve NHS adoption for patient benefit.

** 目的 ** 我们研究项目的目的是开发一种血液检测来检测结直肠癌的早期阶段。早期发现癌症可以使其得到更简单有效的治疗，使其更有可能被治愈。血液测试可以帮助全科医生更有效地将有肠道症状的患者转诊到医院。该测试将允许更快地诊断癌症，以便更快地开始治疗。该测试还可以用于帮助优先考虑患者在治疗肠癌和切除肠息肉后进行结肠镜检查。**背景 ** 肠癌是全世界癌症相关死亡的主要原因。早期发现可以治愈癌症，但由于肠癌的症状很模糊，很难早期诊断。许多有症状的患者被转诊接受昂贵且不愉快的结肠镜检查。大多数结肠镜检查被证明是正常的，可以避免。大量的转诊延误了那些实际上患有潜在癌症的人。真实的需要更快和更少侵入性的检测方法。我们的测试使用激光来检测血液中的癌症活动。一个计算机程序分析信号，判断癌症是否可能。早期的结果表明，血液测试在检测肠癌和可能癌变的息肉方面非常准确。方法 ** 本项目将开发测试设备和软件程序，以备NHS使用。我们将研究将使用该设备的工作人员（医生、采集血液样本的人员和实验室工作人员），以改进其整体设计。这将降低其使用的任何风险，使其尽可能安全。我们还将看看测试是否可以节省成本。该项目有2个工作流：1\。通过与使用者合作，测试并提高器械的安全性。与当前的测试相比，对产品进行经济成本/效益分析 ** 患者/公众参与 ** 我们从项目一开始就有患者参与-确认对可接受和可访问的癌症血液测试的需求是我们开发的核心。我们将与患者和公众合作，设计，交付和传播我们的项目。** 我们将通过政府、学术界、NHS和PPI合作伙伴、社交媒体、出版物和新闻稿分享我们的研究结果，以帮助实现NHS的采用，造福患者。